- Details
- Alicia Morgans and Tia Higano discuss the PRONOUNCE trial, which evaluates the effects of degarelix and leuprolide on cardiovascular events in high-risk prostate cancer patients. Dr. Higano offers insightful explanations concerning the trial's methodology, highlighting its initial slow accrual and early cessation due to a futility analysis. However, she points out that the trial's results, which s...
|
- Details
- Alicia Morgans interviews Nicholas James about the RADICALS trial, a complex study aiming to determine the optimal timing for radiotherapy after surgery and the amount of hormone therapy needed. The first question's data showed that waiting was safe and adjuvant therapy unnecessary. The second question, presented at ESMO, involved pragmatic randomization between zero, six, and 24 months of ADT, re...
|
- Details
- Joining Alicia Morgans is Mark Markowski to discuss the results of a phase Ib/II study of the oral agent sabizabulin, also known as VERU-111. There is an unmet need for additional therapies for men with metastatic castration-resistant prostate cancer (mCRPC). Dr. Markowski shares findings from this study presented at GU ASCO 2022 including recommended phase two dose, what they found in terms of th...
|
- Details
- Sam Chang hosts Yohann Loriot to discuss the LEAP-011 study. The study aims to evaluate the combination of pembrolizumab and lenvatinib for treating metastatic urothelial carcinoma in patients ineligible for cisplatin-based chemotherapy. Despite promising preliminary data from the KEYNOTE-146 study, the LEAP-011 trial finds no significant difference in progression-free survival (PFS) or overall su...
|
- Details
- In a discussion hosted by Alicia Morgans, Neeraj Agarwal delves into the promising results of the COSMIC-021 study. The study focuses on the combination of cabozantinib and atezolizumab for treating patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Agarwal highlights the unique inclusion criteria of the study, which required patients to have progressive measurable disease in...
|
- Details
- Alicia Morgans and Petros Grivas discuss several ongoing or recently launched trials on urothelial carcinoma. Dr. Grivas provides an update on the ECOG-ACRIN 8192 trial for upper tract urothelial carcinoma, which follows the ECOG-ACRIN 8141 trial. The latter set a benchmark for expected pathological complete response rates with standard care chemotherapy for bladder cancer. The upcoming 8192 trial...
|
- Details
- Joining Alicia Morgans, MD, MPH, is Michael Woods, MD, who is the leader of the Alliance trial A031803, a phase II trial studying how well gemcitabine with pembrolizumab works in treating patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG). This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients...
|
- Details
- The University of Minnesota has recently launched the CASPAR randomized Phase III clinical trial of enzalutamide and rucaparib versus enzalutamide and placebo in first-line metastatic castrate-resistant prostate cancer (CRPC). Alicia Morgans is joined by Arpit Rao from the Univesity of Minnesota to discuss the launch and the initial success of this new trial. Biographies: Arpit Rao, MD, MBBS, Assi...
|
- Details
- Joining Alicia Morgans to highlight The Alliance Foundation (AFT-19) trial is Rahul Aggarwal from the UCSF Helen Diller Family Comprehensive Cancer Center. The AFT-19 trial started enrolling in March 2017 and is looking at intensive androgen deprivation therapy (ADT) in high-risk biochemically recurrent prostate cancer (BCRP) patients. It is a randomized open-label, three-arm phase 3 study. AFT-19...
|
- Details
- Petros Grivas discusses the upcoming ASCO GU 2021 meeting that opens on Thursday, February 11, 2021. Dr. Grivas will be presenting a "Trials in Progress" on the study of sacituzumab govitecan (IMMU-132) in metastatic or locally advanced unresectable urothelial cancer (TROPiCS-04). This is a Phase III, global, multicenter, open-label randomized controlled trial in which approximately 600 subjects w...
|
